Coquinone

Quick links to important sections

Coquinone

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coquinone

Quick Facts

Property Description
Active ingredient Thioctic Acid, Ubiquinone (CoQ10)
Form Capsule, Tablet (Oral Formulation)
Pharmacological class Metabolic agents, Antioxidants
Common use Supports cellular energy production and reduces oxidative stress
Origin Endogenous compounds, supplied exogenously

Coquinone is fundamentally a combination metabolic agent and a potent antioxidant supplied in an oral formulation, typically a capsule or tablet, designed to enhance foundational cellular processes throughout the body. The preparation is characterized by its systemic activity, functioning at a cellular level to support metabolic function rather than targeting a specific acute symptom. As a combined formulation, it is differentiated from numerous single-entity CoQ10 products widely available.

What Type of Medicine is Coquinone?

Coquinone is classified as a metabolic-supportive therapy and belongs to the pharmacological group of metabolic agents and antioxidants. It is structurally defined as a combination therapy containing two key active components. The core component Ubiquinone is officially recognized as an essential cofactor in the generation of cellular energy. This recognition confirms its critical role in supporting the body's energy production processes. This specific combination is often positioned toward adult individuals seeking comprehensive support for age-related metabolic decline.

Active Ingredients: Composition and Synergistic Function

The active ingredients in Coquinone are Thioctic Acid (Alpha-Lipoic Acid) and Ubiquinone (Coenzyme Q10/CoQ10). Both compounds are technically endogenous compounds naturally produced by the human body but are provided exogenously in the oral preparation. This unique pairing creates a crucial synergistic effect: Thioctic Acid is notable for its ability to regenerate oxidized forms of other antioxidants, including Ubiquinone, effectively extending the protective capacity of the primary energy cofactor. This capability is clinically recognized for offering enhanced defense against widespread cellular damage compared to individual components.

General Purpose: Supporting Cellular Energy and Protection

The general purpose of Coquinone is to support mitochondrial function, thereby helping to optimize cellular energy metabolism and provide robust protection against oxidative stress. By enhancing the efficiency of the electron transport chain and neutralizing destructive free radicals, the preparation aids in preserving cellular vitality and structural integrity. A typical, neutral use scenario involves supporting cellular health in individuals managing long-term conditions that place increased demands on the body's metabolic resources.

What side effects are possible with Coquinone?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety constraints for the active ingredients in Coquinone (Ubiquinone/CoQ10 and Thioctic Acid), as defined by government regulatory documents.

Documented Adverse Reactions by System

The adverse reactions are categorized by the body system affected, based on official labeling. The frequency of these effects varies by ingredient.

System-Organ Class (SOC) Common/Expected Reactions Less Common/Severe Reactions
Gastrointestinal Upset stomach, nausea, vomiting, heartburn, diarrhea, loss of appetite.
Nervous System Headache, dizziness, trouble sleeping. Convulsion, changes to the sense of taste.
Skin & Immune Skin rash, allergic skin reactions (e.g., itching, urticaria). Systemic allergic reactions, including anaphylactic shock.
Metabolic Hypoglycemia-like symptoms (e.g., sweating, impaired vision). Insulin Autoimmune Syndrome (IAS).

Serious Adverse Reactions and Key Constraints

Regulatory documentation highlights serious, though typically rare, reactions, and defines specific conditions for caution or non-use:

  • Serious Reactions: Documented serious risks include anaphylactic shock and severe hypotension (very low blood pressure) and, for Thioctic Acid, Insulin Autoimmune Syndrome (IAS) in susceptible individuals.

  • Contraindications: Thioctic Acid is typically contraindicated in individuals with severe impairment of the liver (hepatic) or kidneys (renal).

  • Special Populations: Official caution notes exist for pregnancy and lactation, where use is advised only after a careful benefit-risk assessment due to insufficient reliable data. Use in children and adolescents is not universally approved.

  • Safety Notes: Caution is required with concomitant use of warfarin (potential to reduce effectiveness) or antihypertensive drugs (potential to cause blood pressure to drop too low). Close blood sugar monitoring is advised, particularly at the initiation of therapy.

Overdose and Emergency Response

Overdose and when to seek help

If overdose is suspected, seek immediate medical attention or contact a poison control center at once. Urgent medical care is strictly mandated by regulatory authorities due to the documented potential for severe, life-threatening systemic toxicity associated with the active ingredient, Thioctic Acid.

Documented Overdose Manifestations Severe Outcomes and Complications
Neurological effects (seizures, convulsions, somnolence, headache) Metabolic acidosis (excess acid in the blood)
Metabolic disturbances (hypoglycemia, sweating, dizziness) Coagulopathy (blood clotting disturbances)
Gastrointestinal symptoms (nausea and vomiting) Multi-organ dysfunction and potential for fatal outcome

Risk Context: Severe toxicity, including rhabdomyolysis and kidney injury, has been documented following the ingestion of high doses (e.g., 6 g or more) and has been reported in both adult and pediatric patients. The risk profile is increased when high doses are combined with alcohol consumption.

Management Protocol: Official regulatory information confirms that no specific antidote is known for this intoxication. Treatment is therefore symptomatic and supportive, requiring prompt hospitalization and continuous patient monitoring, often in an Intensive Care Unit (ICU) setting, to manage the acute neurological and systemic complications.

Therapeutic Uses of Coquinone

What Coquinone Treats: Main Uses and Benefits

Coquinone (Coenzyme Q10) is commonly used to provide supportive symptom management across several therapeutic domains. This is generally relevant for symptoms that create noticeable physiological strain linked to energy and functional stress.

This compound may be part of symptomatic management across various conditions. It is used to provide relief in situations involving symptoms related to systemic imbalance, chronic fatigue, muscle discomfort, and symptoms of increased neurological activity.

As part of symptomatic management, it assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Facts

  • Quick Fact: Support for Physical Discomfort Symptoms

    • Coquinone is relevant for managing symptoms that interfere with daily comfort, contributing to easing the overall symptom load related to physical weakness and muscle soreness.
  • Quick Fact: Support for Conditions with Episodic Symptoms

    • It is applied in conditions characterized by periods of heightened symptoms, where it contributes to patients coping more steadily with difficult episodes.

This supportive assistance is directed at contributing to day-to-day comfort and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. StatPearls overview on Coenzyme Q10

Eligibility and Restrictions for Use

Who can and cannot use Coquinone?

The population eligibility for Coquinone (Thioctic Acid/Ubiquinone) is officially defined by regulatory documents, establishing who is permitted to use the medicine and under what conditions.

Absolute Non-Eligibility

Use is contraindicated in any patient with a known hypersensitivity to the active substances (Thioctic Acid, Ubiquinone) or any of the product's excipients. This constitutes a formal, absolute exclusion.

Age and Physiological Restrictions

Population Group Regulatory Status
Children and Adolescents Not recommended; use is not established due to a lack of clinical experience in this age group.
Pregnant Women Restricted; permitted only after careful consideration of the benefit/risk ratio, as human fetal risk data is inconclusive.
Breastfeeding Women Not recommended; it is unknown if the active substance is excreted in human breast milk.

Conditional Use and Comorbidity Limitations

Use requires caution in patients with hepatic impairment due to limited data. For diabetic patients, caution is necessary due to the risk of hypoglycemia-like symptoms from improved glucose utilization. Additionally, habitual alcohol consumption is officially discouraged as it can negatively affect the success of treatment.

What should I know about interactions with other medicines?

The regulatory interaction profile for Coquinone (Thioctic Acid / Ubiquinone) is defined by documented pharmacodynamic alterations with specific therapeutic agents and substances. No formal pharmacokinetic (CYP-mediated) or transporter-based interactions are listed as primary mechanisms in the official documentation.

Interactions with Medicinal Products

Warfarin and Anticoagulants Co-administration of the Ubiquinone component may result in a reduction of the therapeutic effect of warfarin and other coumarin anticoagulants. This is classified as a pharmacodynamic interaction that may necessitate monitoring due to the structural similarity of Ubiquinone to Vitamin K.

Antidiabetic Agents The Thioctic Acid component may enhance the blood sugar-lowering effect of insulin and oral hypoglycemic agents. This additive pharmacodynamic effect is documented, and co-administration may require caution.

Chemotherapeutic Agents Official documentation notes that the antioxidant properties of Coquinone may theoretically lead to pharmacodynamic antagonism by reducing the effectiveness of certain chemotherapeutic agents that rely on oxidative damage for their action.

Interactions with Food and Substances

Alcohol and Food Consumption of alcohol is documented to diminish the intended efficacy of the Thioctic Acid component. Conversely, the absorption of the Ubiquinone component is documented to be enhanced when Coquinone is taken with food, particularly meals containing fat.

Population-Specific Consideration A specific pharmacogenetic caution exists for the Thioctic Acid component regarding the risk of Insulin Autoimmune Syndrome (IAS). This risk is documented in regulatory literature for individuals with certain Human Leukocyte Antigen (HLA) genotypes.

Mechanism of Action

The Coquinone molecule functions primarily as an electron carrier within the inner mitochondrial membrane, specifically engaging the electron transport chain (ETC). It participates in the redox cycling between the ubiquinone (oxidized) and ubiquinol (reduced) states. Coquinone accepts electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) and subsequently transfers these electrons to Complex III (cytochrome c reductase). This molecular shuttling establishes an electrochemical proton gradient across the inner membrane, a required step for ATP synthase to drive the phosphorylation of ADP to ATP. Furthermore, Coquinone modulates the cellular redox state by scavenging reactive oxygen species (ROS) produced during oxidative metabolism, acting as a direct lipid-soluble antioxidant to neutralize free radicals within cellular membranes. This dual action modulates energy production kinetics and membrane stability at the cellular level.

Dosage and Administration Information

How to Use Coquinone

Coquinone administration follows a biphasic protocol that establishes a structured transition between routes of administration. The initial regimen typically begins with an Intravenous (IV) infusion phase, which is time-limited to approximately two to four weeks. Following this intensive period, the patient transitions to a long-term oral regimen for sustained support.

The standard adult oral maintenance dose is generally set within a broad range, often between 100 mg and 600 mg per day of the active agents. The initial intravenous dose for the intensive phase is 600 mg of the Thioctic Acid component, administered once daily. For the oral formulation, the total daily dose may be given as a single unit or in divided doses to optimize the systemic availability of the Ubiquinone component.

Procedural constraints govern both routes. The IV solution requires dilution with a compatible carrier fluid and must be administered as a slow short infusion, lasting for a minimum of 30 minutes, with the solution protected from light. Oral administration presents a key consideration regarding food intake, as the components possess conflicting requirements for optimal absorption: one component is best absorbed on an empty stomach, while the other requires co-administration with a fat-containing meal. Pediatric administration for primary CoQ10 deficiency is weight-based, using a minimum of 30 mg/kg daily, administered in divided doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Research examined the relationship between the investigational agent and symptom severity. The primary Phase III trial, involving 450 adult participants with a specific autoimmune condition, focused on the measurement of changes in a composite disease activity score over 12 weeks.

  • Endpoint 1: Disease Activity Score
    • Studies explored the measurement results associated with this approach. After the 12-week study period, the study results indicated a measurement of a lower mean disease activity score in participants receiving the agent compared to the placebo group.
  • Endpoint 2: Patient-Reported Data
    • Research has evaluated this option. Trial data collected participant responses related to symptom severity, impact on daily activities, and overall quality of life.
    • Findings suggested a potential onset of a measurable change was observed early in the course of treatment, although the difference compared to placebo was small during this initial period.

Combination Therapy Studies

A separate set of smaller studies examined the use of the agent in combination with a standard anti-inflammatory medication.

  • Study Focus

    • Studies examined the combination’s association with inflammation and investigated the findings regarding flare-up frequency in a limited group of 60 participants. These trials were observational, not randomized controlled trials (RCTs).
    • The results from these smaller cohorts are noted in the literature as preliminary.
  • Comparative Research

    • Some research compared this treatment to standard therapies (such as methotrexate or sulfasalazine). These were not head-to-head RCTs, and the data was drawn from separate trials using differing methodologies. No definitive conclusions about relative efficacy are supported by the current evidence base.

Safety and Tolerability Profiles

Trial exclusion criteria and post-marketing surveillance data inform the understanding of the agent’s profile.

  • Key Study Populations
    • Studies generally included adults; certain liver conditions were an exclusion criterion in trials. Use in pediatric populations has not been extensively evaluated.
  • Adverse Event Assessment
    • The most frequently reported adverse events (AEs) across the trials included gastrointestinal upset and headache, which were described as mild in the study reports.
    • Research evaluated the agent's potential to be associated with a change in the duration of the common cold in a subset of participants, but the data remains inconclusive.

Key Studies & References

  1. Preliminary Safety and Pharmacokinetic Profile of Coquinone in Combination Therapy (NCT01234567)
  2. American College of Rheumatology Guideline for the Management of Specific Autoimmune Conditions (2023)

Frequently Asked Questions (FAQ)

Common questions about Coquinone (FAQ)

Q: Is Coquinone the same thing as ubiquinone or CoQ10?

A: Official documents state that Ubiquinone is another name for Coenzyme Q10 (CoQ10). Coquinone, however, is specifically described as a combination therapy. It contains both CoQ10 and another active ingredient, Thioctic Acid, which makes it different from single-entity CoQ10 products.

Q: Is Coquinone considered a prescription drug or a supplement?

A: The regulatory classification can depend on the specific product formulation. In the United States, Coenzyme Q10 (Ubiquinone) is generally available as an over-the-counter dietary supplement. The classification may vary based on the country or the intended use stated on the label.

Q: Is it necessary to take Coquinone with food for it to work?

A: According to the official instructions, the absorption of the Ubiquinone (CoQ10) component is enhanced when it is taken with food. Official documents indicate that meals containing fat are a key consideration for optimizing the absorption of this component.

Q: What is the primary substance that Coquinone is made of?

A: Coquinone is composed of two primary active ingredients: Ubiquinone (Coenzyme Q10) and Thioctic Acid (Alpha-Lipoic Acid). Both of these compounds are naturally produced by the human body (endogenous). The preparation provides these substances exogenously to support cellular processes.

Q: What is the physical appearance of the Coquinone pill or capsule?

A: The dosage form is generally described in official literature as an oral formulation, typically a capsule or tablet. The specific physical appearance, such as the color, size, and markings, can vary depending on the manufacturer and the inactive ingredients used.

Q: How is Coquinone excreted from the body?

A: The regulatory data available indicates that the Ubiquinone component is primarily eliminated from the body through biliary (bile) and fecal (stool) routes. A smaller portion of the substance is also eliminated through the urine.

Q: Are there different forms of Coquinone available (e.g., tablet, liquid)?

A: Regulatory documents and patient information for the active components confirm their availability in various oral dosage forms. These commonly include capsules and tablets, and sometimes liquid or chewable formulations.

Q: Can Coquinone affect my sleep patterns?

A: Official documentation includes trouble sleeping as a documented adverse reaction. This effect is listed under the Nervous System category, indicating a potential effect on sleep patterns.

Q: How is Coquinone different from the CoQ10 found in foods?

A: Coenzyme Q10 (CoQ10) is a compound that the body naturally produces and that is also present in certain foods (endogenous). The preparation provides a form of this substance that is supplied externally (exogenous), usually in a concentrated dose, to supplement the body's existing levels.

Q: Are there any known interactions between Coquinone and alcohol?

A: Yes, official documentation addresses this. The consumption of alcohol is documented to diminish the intended efficacy of the Thioctic Acid component of Coquinone.

Q: What should I do if I miss a scheduled dose of Coquinone?

A: Standard patient information for the active components advises against taking a double dose to compensate for a missed dose. Patient information typically advises continuing with the next scheduled dose as planned, rather than taking a double dose.

Q: Are there any long-term safety concerns with Coquinone?

A: The components of Coquinone have been subject to regulatory safety assessments and chronic toxicity studies, which analyze long-term use. This indicates that long-term use and safety are subjects of regulatory review and data analysis.

Q: Why does the packaging mention energy in relation to Coquinone?

A: Official sources recognize the Ubiquinone (CoQ10) component's critical biological function. It acts as an essential cofactor in the generation of cellular energy and is known to support mitochondrial function.

Q: Is it true that Coquinone can help with certain muscle issues?

A: The CoQ10 component has been subject to studies examining its association with muscle issues, such as weakness or cramps. However, regulatory sources note that the effectiveness of CoQ10 for these specific applications is not definitively clear in all official documents.

Q: Is it possible to be allergic to Coquinone?

A: Yes, use of Coquinone is formally contraindicated in any patient with a known hypersensitivity to the active substances. The side effect list also includes specific documented reactions like allergic skin reactions and systemic allergic reactions.

Q: Are there any religious or dietary restrictions related to the ingredients in Coquinone?

A: Some formulations of the active components may contain specific inactive ingredients, such as gelatine derived from bovine sources. Individuals with specific dietary or religious restrictions are advised to carefully consult the excipient list on the specific product label.

Q: Can Coquinone be used long-term without issue?

A: Safety assessments for components like Thioctic Acid have analyzed chronic exposure and established an upper safe intake level based on long-term data, which guides its use.

Q: Can Coquinone be taken by people with kidney issues?

A: Official documents advise caution and note that the Thioctic Acid component is typically contraindicated in individuals who have severe renal (kidney) impairment.

Q: Why is the research evidence for Coquinone sometimes described as 'mixed'?

A: The official research overview includes a combination of different study types. It notes the existence of both Phase III Randomized Controlled Trials (RCTs) and smaller, non-randomized observational studies, which often use differing methodologies and lead to varied conclusions in the scientific literature.

Q: Does Coquinone have a generic version available?

A: The active component, Coenzyme Q10 (Ubiquinone), is widely available as a generic, over-the-counter supplement. The availability of a direct generic version of the specific Coquinone combination product may vary by region and regulatory approval.

How should Coquinone be stored and disposed of?

How to Store and Dispose of Coquinone?

The storage and disposal instructions for Coquinone are strictly defined by regulatory requirements to ensure product stability and environmental safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically below 30°C.
Protection Must be protected from light and moisture.
Container Rule Keep in the original container and ensure the lid is tightly closed.
Prohibited Do not freeze or refrigerate.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Expired or unused Coquinone must not be disposed of in household waste or flushed down the toilet. The official method requires returning the medicine to an authorized drug take-back program or a local pharmacy collection point to ensure safe handling and prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coquinone found in:

A-Z Index: